https://scholars.lib.ntu.edu.tw/handle/123456789/496134
標題: | Pioglitazone and bladder cancer: A population-based study of Taiwanese | 作者: | CHIN-HSIAO TSENG | 公開日期: | 2012 | 卷: | 35 | 期: | 2 | 起(迄)頁: | 278-280 | 來源出版物: | Diabetes Care | 摘要: | OBJECTIVE - The association between pioglitazone and bladder cancer has not been investigated in Asians. We aimed to investigate this association. RESEARCH DESIGN AND METHODS - A total of 1,000,000 individuals were randomly sampled from the National Health Insurance database, and incident cases of bladder cancer during the period from 1 January 2006 to 31 December 2009 were analyzed among 54,928 patients with type 2 diabetes and without previous bladder cancer. RESULTS - Among 165 incident case subjects, 10 (0.39%) were ever users and 155 (0.30%) were never users of pioglitazone (adjusted hazard ratio in full model 1.305 [95% CI 0.661-2.576]). All bladder cancer in ever users occurred within a duration of therapy <24 months, suggesting an early effect of pioglitazone on bladder cancer or late use of pioglitazone in high-risk patients. CONCLUSIONS - The association between pioglitazone and bladder cancer was not significant. However, confirmation of this finding is required because of the possible lack of statistical power owing to the small number of events. ? 2012 by the American Diabetes Association. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859053613&doi=10.2337%2fdc11-1449&partnerID=40&md5=a3b9b445f70cea3bc40fc4c430401b3a https://scholars.lib.ntu.edu.tw/handle/123456789/496134 |
ISSN: | 0149-5992 | DOI: | 10.2337/dc11-1449 | SDG/關鍵字: | pioglitazone; adult; article; bladder cancer; cancer incidence; controlled study; disease association; drug use; female; high risk patient; human; major clinical study; male; non insulin dependent diabetes mellitus; population research; Taiwan; Asian Continental Ancestry Group; Female; Humans; Hypoglycemic Agents; Male; Thiazolidinediones; Urinary Bladder Neoplasms |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。